$72.37 $1.66 (2.3%)

04:00 PM EST on 12/06/19

CRISPR Therapeutics (NASDAQ:CRSP)

CAPS Rating: 4 out of 5

Current Price $72.37 Mkt Cap $4.3B
Open $71.48 P/E Ratio 0.00
Prev. Close $70.71 Div. (Yield) $0.00 (0.0%)
Daily Range $70.57 - $72.70 Volume 893,463
52-Wk Range $27.15 - $74.00 Avg. Daily Vol. 1,131,738

Caps

How do you think NASDAQ:CRSP will perform against the market?

Add Stock to CAPS Watchlist

All Players

131 Outperform
3 Underperform
 

All-Star Players

38 Outperform
2 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:CRSP Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:CRSP VS S&P 500 (SPY)

NASDAQ:CRSP Summary

Fools bullish on NASDAQ:CRSP are also bullish on:

Fools bearish on NASDAQ:CRSP are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about CRSP.

Recs

0
Member Avatar dcclf (< 20) Submitted: 11/1/2019 1:07:40 AM : Outperform Start Price: $52.08 NASDAQ:CRSP Score: +35.69

Crispr Therapeutics AG (CRSP) is a very professional outfit. Since its de novo in late 2016, the company has always presented itself in the most intelligible, concise, and scrupulous manner. From international conference presentations to downloadable PDF articles hosted on their business website; B2B collaborative ventures to sole experimental endeavors, they have always tried to put their “best foot forward.” Crispr has never folded under political pressure nor baseless market rhetoric. It maintains tight reigns on the promulgation of its progress and intellectual property developments. Crispr seems very “patient-focused” and appears to want to provide permanent, non-repercussive, and precisive treatments for a myriad of serious diseases. If the company reports positive progress from its first American patient, Victoria Gray, the market’s response will be in epic proportion. You cannot use typical fundamental or technical analysis to gauge social sentiment in regards to this company’s valuation or prospective ROI; the company has the potential to make history and disrupt the medical industry as we know it.

Recs

0
Member Avatar TMFmarkprvulovic (< 20) Submitted: 10/7/2019 1:27:59 AM : Outperform Start Price: $39.85 NASDAQ:CRSP Score: +72.87

The gene-editing market as a whole is in a great position and CRISPR has some strong drug candidates currently being developed.

Recs

0
Member Avatar SurfingCabarete (29.92) Submitted: 7/9/2019 12:17:33 PM : Outperform Start Price: $47.69 NASDAQ:CRSP Score: +45.66

pure gamble on gene editing

Leaderboard

Find the members with the highest scoring picks in CRSP.

Score Leader

CMFMLove

CMFMLove (43.16) Score: +384.21

I'm generally bad at CAPS but I may have gotten this pick right. There's a long way to go, however, until we see commercial results from this technology.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
CMFMLove 43.16 6/13/2017 Outperform 5Y $14.10 +413.26% +29.05% +384.21 1 Comment
Momentum21 79.17 10/24/2016 Outperform 5Y $14.05 +415.09% +46.59% +368.50 0 Comment
Playa14 < 20 6/9/2017 Outperform 5Y $15.13 +378.32% +28.99% +349.33 0 Comment
prankjt17530 44.24 2/13/2017 Outperform 5Y $15.21 +375.81% +35.66% +340.14 0 Comment
SHOPNVDA < 20 6/26/2017 Outperform 5Y $16.84 +329.75% +29.09% +300.66 0 Comment
Capitalism 81.16 5/15/2017 Outperform 5Y $17.05 +324.46% +31.12% +293.34 1 Comment
TMFFishBiz 34.71 11/13/2017 Outperform 5Y $17.91 +304.08% +21.90% +282.18 0 Comment
JF9383 71.48 12/6/2017 Outperform 5Y $18.44 +292.46% +19.77% +272.69 0 Comment
jeepdrew222 66.16 12/12/2017 Outperform 5Y $18.61 +288.88% +18.11% +270.77 0 Comment
odocoileus 20.99 10/5/2017 Outperform 5Y $19.05 +279.90% +24.18% +255.71 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CRSP.